JP2008526888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526888A5 JP2008526888A5 JP2007550547A JP2007550547A JP2008526888A5 JP 2008526888 A5 JP2008526888 A5 JP 2008526888A5 JP 2007550547 A JP2007550547 A JP 2007550547A JP 2007550547 A JP2007550547 A JP 2007550547A JP 2008526888 A5 JP2008526888 A5 JP 2008526888A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- optionally substituted
- group
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 8-azabicyclo [3.2.1] oct-8-yl Chemical group 0.000 claims 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 15
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 6
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 230000037182 bone density Effects 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 230000001568 sexual effect Effects 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 238000002657 hormone replacement therapy Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 208000005494 xerophthalmia Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010013883 Dwarfism Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000036119 Frailty Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010058359 Hypogonadism Diseases 0.000 claims 2
- 208000030663 Libido disease Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 206010049565 Muscle fatigue Diseases 0.000 claims 2
- 208000020221 Short stature Diseases 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- 230000021595 spermatogenesis Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64284105P | 2005-01-10 | 2005-01-10 | |
| US60/642,841 | 2005-01-10 | ||
| PCT/US2006/000733 WO2006076317A2 (en) | 2005-01-10 | 2006-01-09 | Aminophenyl derivatives as selective androgen receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526888A JP2008526888A (ja) | 2008-07-24 |
| JP2008526888A5 true JP2008526888A5 (https=) | 2009-02-26 |
| JP5203712B2 JP5203712B2 (ja) | 2013-06-05 |
Family
ID=36591321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550547A Expired - Fee Related JP5203712B2 (ja) | 2005-01-10 | 2006-01-09 | 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7585877B2 (https=) |
| EP (1) | EP1836202B1 (https=) |
| JP (1) | JP5203712B2 (https=) |
| KR (1) | KR20070112775A (https=) |
| CN (1) | CN101119993B (https=) |
| AU (1) | AU2006205066B2 (https=) |
| CA (1) | CA2594340C (https=) |
| MX (1) | MX2007008334A (https=) |
| NZ (1) | NZ555974A (https=) |
| RU (1) | RU2007130558A (https=) |
| WO (1) | WO2006076317A2 (https=) |
| ZA (1) | ZA200705458B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070004679A1 (en) * | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| CN101119993B (zh) | 2005-01-10 | 2015-03-04 | 阿卡蒂亚药品公司 | 作为选择性雄激素受体调节剂的氨基苯基衍生物 |
| US20060173037A1 (en) * | 2005-01-10 | 2006-08-03 | Nathalie Schlienger | Aminophenyl derivatives as selective androgen receptor modulators |
| JP5070054B2 (ja) * | 2005-08-01 | 2012-11-07 | 武田薬品工業株式会社 | 環状アミン化合物 |
| PL2018380T3 (pl) | 2006-05-19 | 2012-05-31 | Abbvie Bahamas Ltd | Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN |
| JP5241507B2 (ja) | 2006-11-30 | 2013-07-17 | 武田薬品工業株式会社 | 環状アミン化合物 |
| ME01579B (me) | 2007-08-07 | 2014-09-20 | Takeda Pharmaceuticals Co | Derivati pirolidin-2-ona kao modulatori androgenskih receptora |
| CA2716320C (en) | 2008-02-22 | 2014-01-28 | Radius Health, Inc. | Selective androgen receptor modulators |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
| HUE030072T2 (en) | 2010-05-12 | 2017-04-28 | Radius Health Inc | Therapeutic prescriptions |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| AU2012288457B2 (en) * | 2011-07-27 | 2016-03-24 | Novartis Ag | Pyrazoline derivatives and their use as selective androgen receptor modulators |
| WO2014125121A1 (en) | 2013-02-18 | 2014-08-21 | Acadia Pharmaceuticals Inc. | Compounds and compositions for treating neurodegenerative diseases |
| WO2014149998A1 (en) * | 2013-03-15 | 2014-09-25 | Lin, Qing | Systemic administration of androgen in treating dry eye syndrome |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CN106103434B (zh) * | 2014-05-29 | 2019-05-10 | 大鹏药品工业株式会社 | 四氢吡啶并嘧啶化合物或其盐 |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| CN107709290B (zh) * | 2015-04-21 | 2023-02-28 | Gtx公司 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
| WO2017090719A1 (ja) * | 2015-11-27 | 2017-06-01 | 大鵬薬品工業株式会社 | 縮環ピリミジン化合物又はその塩 |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| MX389702B (es) | 2016-06-22 | 2025-03-20 | Ellipses Pharma Ltd | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形性形態 |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| MX2020013713A (es) | 2018-07-04 | 2021-03-02 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
| WO2020051344A1 (en) | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| EP3924328A1 (en) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| WO2022212631A1 (en) * | 2021-03-31 | 2022-10-06 | Taiho Pharmaceutical Co., Ltd. | Treatment of patients metastatic castration-resistant prostate cancer with an androgen receptor antagonist |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140992B (nl) * | 1963-07-06 | 1974-01-15 | Kalle Ag | Kopieermateriaal, dat een lichtgevoelig diazoniumzout bevat en werkwijze voor het bereiden van dat zout. |
| DE3100535A1 (de) | 1981-01-10 | 1982-08-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel" |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| DE4404198A1 (de) | 1994-02-10 | 1995-08-17 | Henkel Kgaa | 2-Fluor-6-nitroaniline |
| US5507798A (en) * | 1994-09-14 | 1996-04-16 | United States Surgical Corporation | Surgical needle-suture attachment for controlled suture release |
| PT792273E (pt) | 1994-11-15 | 2003-06-30 | Upjohn Co | Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas |
| GB9510459D0 (en) | 1995-05-24 | 1995-07-19 | Zeneca Ltd | Bicyclic amines |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| WO1999061917A1 (en) | 1998-05-26 | 1999-12-02 | Koninklijke Philips Electronics N.V. | Label for making a charge-transfer fluorescent probe |
| WO1999064417A2 (en) * | 1998-06-05 | 1999-12-16 | Astrazeneca Ab | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
| CN1129581C (zh) * | 1998-09-22 | 2003-12-03 | 山之内制药株式会社 | 氰基苯基衍生物 |
| ATE259804T1 (de) * | 1998-11-27 | 2004-03-15 | Neurosearch As | 8-azabicyclo(3.2.1)okt-2-en- und -oktanderivate |
| DE60137728D1 (de) | 2000-08-24 | 2009-04-02 | Univ Tennessee Res Foundation | Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung |
| JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| US7214690B2 (en) | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
| US20040087548A1 (en) * | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| WO2003011824A1 (en) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| EP1433771B1 (en) | 2001-08-16 | 2009-12-30 | Ube Industries, Ltd. | Process for preparation of cyclododecanone |
| US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| PL375042A1 (en) | 2002-08-12 | 2005-11-14 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| DE10322108B4 (de) * | 2003-05-09 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit |
| JP2007500245A (ja) | 2003-06-10 | 2007-01-11 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| EP1687274A1 (en) | 2003-11-20 | 2006-08-09 | Warner-Lambert Company LLC | Androgen receptor modulators |
| US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| EP1756101A2 (en) | 2004-05-17 | 2007-02-28 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| WO2006013887A1 (ja) | 2004-08-03 | 2006-02-09 | Chugai Seiyaku Kabushiki Kaisha | 新規イミダゾリジン誘導体 |
| CN101119993B (zh) * | 2005-01-10 | 2015-03-04 | 阿卡蒂亚药品公司 | 作为选择性雄激素受体调节剂的氨基苯基衍生物 |
| US20060173037A1 (en) * | 2005-01-10 | 2006-08-03 | Nathalie Schlienger | Aminophenyl derivatives as selective androgen receptor modulators |
-
2006
- 2006-01-09 CN CN200680002003.2A patent/CN101119993B/zh not_active Expired - Fee Related
- 2006-01-09 EP EP06733660.2A patent/EP1836202B1/en not_active Expired - Lifetime
- 2006-01-09 WO PCT/US2006/000733 patent/WO2006076317A2/en not_active Ceased
- 2006-01-09 JP JP2007550547A patent/JP5203712B2/ja not_active Expired - Fee Related
- 2006-01-09 CA CA2594340A patent/CA2594340C/en not_active Expired - Fee Related
- 2006-01-09 KR KR1020077018305A patent/KR20070112775A/ko not_active Withdrawn
- 2006-01-09 US US11/329,267 patent/US7585877B2/en not_active Expired - Fee Related
- 2006-01-09 ZA ZA200705458A patent/ZA200705458B/xx unknown
- 2006-01-09 RU RU2007130558/04A patent/RU2007130558A/ru not_active Application Discontinuation
- 2006-01-09 AU AU2006205066A patent/AU2006205066B2/en not_active Ceased
- 2006-01-09 MX MX2007008334A patent/MX2007008334A/es not_active Application Discontinuation
- 2006-01-09 NZ NZ555974A patent/NZ555974A/en not_active IP Right Cessation
-
2009
- 2009-06-30 US US12/495,514 patent/US20090270449A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526888A5 (https=) | ||
| RU2007130558A (ru) | Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов | |
| KR101752124B1 (ko) | 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 | |
| AU2014291711B2 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP6122055B2 (ja) | 核内受容体結合剤 | |
| JP2019031560A5 (https=) | ||
| EP1682545B1 (en) | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation | |
| JP2021508686A5 (https=) | ||
| JP2011513468A5 (https=) | ||
| JP2006510716A5 (https=) | ||
| JP7051853B2 (ja) | ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド | |
| JP2014502982A5 (https=) | ||
| JP2009524670A5 (https=) | ||
| CA2606087A1 (en) | Novel oxadiazole derivatives and their medical use | |
| JP2017509676A5 (https=) | ||
| JP2019511466A5 (https=) | ||
| JP2019532974A5 (https=) | ||
| JP5822079B2 (ja) | 疼痛治療剤 | |
| JP2013530139A (ja) | ヒドロキシアルキルベンジルピラゾール類およびその使用 | |
| JP2023532658A (ja) | 睡眠時無呼吸の治療のためのアルファ２－アドレナリン受容体サブタイプｃ（アルファ－２ｃ）拮抗薬とｔａｓｋ１／３チャネル遮断薬の組合せ | |
| US9051326B2 (en) | Pyrazoline derivatives and their use as selective androgen receptor modulators | |
| JP2025500346A (ja) | 睡眠時無呼吸の治療のためのα２－アドレナリン受容体サブタイプＣ（アルファ－２Ｃ）アンタゴニストとムスカリン受容体アンタゴニストとの組合せ | |
| WO2025176104A9 (en) | Heterocyclic derivatives having s1p3 receptor antagonistic activity | |
| JP2025500344A (ja) | 睡眠時無呼吸の治療のためのα２－アドレナリン受容体サブタイプＣ（アルファ－２Ｃ）アンタゴニストとノルエピネフリン再取込み阻害薬との組合せ | |
| JP2020536070A (ja) | 新規な塩 |